BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosimilar monoclonal an...
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an innovative AntibodyDrug Conjugate (ADC) targeting...
GUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing innovative therapies and biosimilars, andSteinCares, one of Latin America’s leading specialty healthcare companies,announced today a new licensing agreement for two biosimilars u...
